IgH-reprogrammed B cells to produce HIV broadly neutralizing antibodies in mice
Official title: in vivo modeling of IgH-reprogrammed B cells in mice
Funded at Scripps Research Institute, the · NIH-11404860 · Data updated 2026-11-12
A mouse study will reprogram a patient's B cells to wear HIV-neutralizing antibodies on their surface, with the goal of generating durable immune protection.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Scripps Research Institute, the NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project start | September 5, 2025 |
| Project end | June 30, 2030 |
| Funding year | 2026 |
| Award (this year) | $701,107 |
| NIH project number | 5P01HL183482-02 |
| Project ID | NIH-11404860 on NIH RePORTER |
Who could benefit from this research
✓Could help
People living with HIV or those at risk could benefit from future therapies that induce durable bnAb responses.
✕Less likely to help
This specific study is in mice and does not involve patient recruitment.
What this research studies
This project uses genetic editing to reprogram B cells in mice so they express powerful HIV antibodies as B-cell receptors. It builds a mouse model to test memory responses and antibody levels after booster doses, aiming for long-lasting protection. Researchers will optimize reprogramming methods, vaccination settings, and delivery approaches to boost durable bnAb responses and assess responses to variants that could escape antibodies.
Why it matters
Potential benefit: If successful, this work could inform strategies to induce durable HIV immunity and guide future clinical approaches toward a functional cure.
How similar studies have gone: Previous models have shown that bnAbs can be boosted and maintained in memory, supporting this line of research.
Where this research is happening
-
Scripps Research Institute, the
La Jolla, United States Active
Researchers
- Principal investigator: Voss, James Even — Scripps Research Institute, the
- Study coordinator: Voss, James Even
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.